Natera, Inc. (NTRA) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $221.10 (+1.90%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Oct 27, 2025 | Navann Ty | BNP Paribas | $172.00 | -22.2% |
| Sep 22, 2025 | Brandon Couillard | Wells Fargo | $175.00 | -20.9% |
| Sep 2, 2025 | Conor McNamara | RBC Capital | $268.00 | +21.2% |
| Aug 10, 2025 | Patrick Wood | Morgan Stanley | $195.00 | -11.8% |
| Nov 13, 2024 | Tycho Peterson | Jefferies | $182.00 | -17.7% |
| Nov 13, 2024 | Catherine Ramsey Schulte | Robert W. Baird | $160.00 | -27.6% |
| Oct 29, 2024 | Kyle Mikson | Canaccord Genuity | $150.00 | -32.2% |
| Sep 13, 2024 | Dave Westenberg | Piper Sandler | $150.00 | -32.2% |
| Aug 27, 2024 | Kyle Mikson | Canaccord Genuity | $145.00 | -34.4% |
| Aug 13, 2024 | Tejas Savant | Morgan Stanley | $132.00 | -40.3% |
| Aug 9, 2024 | Catherine Ramsey Schulte | Robert W. Baird | $120.00 | -45.7% |
| Jun 25, 2024 | Doug Schenkel | Wolfe Research | $135.00 | -38.9% |
| Jun 3, 2024 | Tycho Peterson | Jefferies | $142.00 | -35.8% |
| May 14, 2024 | David Westenberg | Piper Sandler | $120.00 | -45.7% |
| May 13, 2024 | Mark Massaro | BTIG | $125.00 | -43.5% |
| May 10, 2024 | Catherine Ramsey Schulte | Robert W. Baird | $117.00 | -47.1% |
| Apr 5, 2024 | Eve Burstein | Bernstein | $120.00 | -45.7% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $70.00 | -68.3% |
| May 15, 2022 | David Westenberg | Piper Sandler | $60.00 | -72.9% |
| May 25, 2021 | Sandy Draper | Guggenheim | $129.00 | -41.7% |
Top Analysts Covering NTRA
NTRA vs Sector & Market
| Metric | NTRA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.27 | 2.24 | 2.40 |
| Analyst Count | 11 | 8 | 19 |
| Target Upside | +22.9% | +11475.0% | +17.1% |
| P/E Ratio | -131.47 | 4.03 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.62B | $2.67B | $2.68B | 15 |
| 2027-03-31 | $741M | $748M | $757M | 5 |
| 2027-06-30 | $766M | $773M | $782M | 6 |
| 2027-09-30 | $804M | $812M | $822M | 9 |
| 2027-12-31 | $852M | $860M | $870M | 5 |
| 2028-03-31 | $836M | $844M | $854M | 4 |
| 2028-06-30 | $891M | $900M | $911M | 6 |
| 2028-09-30 | $954M | $963M | $975M | 9 |
| 2028-12-31 | $1.03B | $1.04B | $1.06B | 4 |
| 2029-12-31 | $4.29B | $4.37B | $4.48B | 5 |
| 2030-12-31 | $4.94B | $5.03B | $5.16B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-2.20 | $-1.80 | $-1.29 | 12 |
| 2027-03-31 | $-0.27 | $-0.26 | $-0.26 | 3 |
| 2027-06-30 | $-0.24 | $-0.23 | $-0.23 | 3 |
| 2027-09-30 | $-0.12 | $-0.11 | $-0.11 | 4 |
| 2027-12-31 | $-0.01 | $-0.01 | $-0.01 | 3 |
| 2028-03-31 | $0.10 | $0.10 | $0.10 | 4 |
| 2028-06-30 | $0.19 | $0.19 | $0.19 | 4 |
| 2028-09-30 | $0.31 | $0.31 | $0.32 | 6 |
| 2028-12-31 | $0.41 | $0.42 | $0.43 | 4 |
| 2029-12-31 | $1.74 | $1.78 | $1.84 | 10 |
| 2030-12-31 | $4.18 | $4.28 | $4.42 | 5 |
Frequently Asked Questions
What is the analyst consensus for NTRA?
The consensus among 11 analysts covering Natera, Inc. (NTRA) is Buy with an average price target of $249.57.
What is the highest price target for NTRA?
The highest price target for NTRA is $268.00, set by Conor McNamara at RBC Capital on 2025-09-02.
What is the lowest price target for NTRA?
The lowest price target for NTRA is $60.00, set by David Westenberg at Piper Sandler on 2022-05-15.
How many analysts cover NTRA?
11 analysts have issued ratings for Natera, Inc. in the past 12 months.
Is NTRA a buy or sell right now?
Based on 11 analyst ratings, NTRA has a consensus rating of Buy (2.27/5) with a +22.9% upside to the consensus target of $249.57.
What are the earnings estimates for NTRA?
Analysts estimate NTRA will report EPS of $-1.80 for the period ending 2026-12-31, with revenue estimated at $2.67B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.